Saxagliptin linked to improved albumin/creatinine ratios

October 25, 2016

(HealthDay)—For patients with type 2 diabetes, saxagliptin is associated with improvement in the albumin/creatinine ratio (ACR), according to a study published online Oct. 17 in Diabetes Care.

Ofri Mosenzon, M.D., from the Hadassah Hebrew University Hospital in Jerusalem, and colleagues studied renal outcomes of 16,492 with type 2 diabetes randomized to versus placebo and followed for a median of 2.1 years.

The researchers found that from baseline to the end of the trial, treatment with saxagliptin was associated with improvement in and/or less deterioration in ACR categories for individuals with baseline normoalbuminuria, microalbuminuria, and macroalbuminuria (P = 0.021; P < 0.001; P = 0.049, respectively). The difference in mean ACR change between the saxagliptin and placebo arms was −19.3 mg/g, −105 mg/g, and −245.2 mg/g for estimated (eGFR) of >50 mL/min/BSA, 50≥ eGFR ≥30 mL/min/BSA, and <30 mL/min/BSA, respectively (P = 0.033; P = 0.011; P = 0.086). There was reduction in ACR with saxagliptin on analysis of ACR as a continuous variable. There was no correlation between the change in ACR and that in glycated hemoglobin. The saxagliptin and placebo groups had similar change in eGFR. Similar safety renal outcomes were also seen for the groups.

"Treatment with saxagliptin improved ACR, even in the normoalbuminuric range, without affecting eGFR," the authors write. "The beneficial effect of saxagliptin on albuminuria could not be explained by its effect on glycemic control."

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Bristol-Myers Squibb, which funded the trial.

Explore further: Saxagliptin not linked to increased fracture risk in T2DM

More information: Full Text (subscription or payment may be required)

Related Stories

Saxagliptin not linked to increased fracture risk in T2DM

September 25, 2015
(HealthDay)—For patients with type 2 diabetes, treatment with saxagliptin is not associated with increased fracture risk, according to a study published online Sept. 10 in Diabetes Care.

Impact of T2DM meds on heart failure hospitalization explored

January 19, 2016
(HealthDay)—For patients with type 2 diabetes, there is no association between hospitalization for heart failure and treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) versus sulfonylureas (SUs) or treatment with ...

Low HDL-C, high TG increase risk for diabetic kidney disease

October 12, 2016
(HealthDay)—For patients with diabetes, low high-density lipoprotein cholesterol (HDL-C) and high triglyceride (TG) levels are associated with increased risk of diabetic kidney disease (defined as low estimated glomerular ...

Albuminuria linked to higher nighttime SBP in hypertension

August 22, 2016
(HealthDay)—For patients with hypertension, albuminuria is associated with higher nighttime systolic blood pressure (SBP), according to a study published online Aug. 11 in Diabetes Care.

Decline in eGFR mainly linear in type 1 diabetes

September 22, 2016
(HealthDay)—For patients with type 1 diabetes, the decline of estimated glomerular filtration rate (eGFR) is mainly linear, according to a study published online Sept. 19 in Diabetes Care.

Gliptin treatment tied to higher risk of acute pancreatitis

September 27, 2016
(HealthDay)—Gliptin treatment is associated with increased acute pancreatitis risk, according to research published online Sept. 22 in Diabetes Care.

Recommended for you

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

New measure of insulin-making cells could gauge diabetes progression, treatment

August 10, 2017
Researchers at the University of Wisconsin-Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.

Pioneering immunotherapy shows promise in type 1 diabetes

August 9, 2017
It may be possible to 'retrain' the immune system to slow the progression of type 1 diabetes, according to results of a clinical trial published today in the journal Science Translational Medicine.

Online team-based game helps patients with diabetes lower blood glucose

August 8, 2017
Researchers from Brigham and Women's Hospital and the Veterans Affairs Boston Healthcare System have found that an online, team-based game designed to teach patients about diabetes self-management had a sustained and meaningful ...

Oxidative stress biomarkers don't always signal diabetes risk

August 7, 2017
High levels of compounds found in the body that are commonly associated with oxidative damage may actually be a good sign for some people, according to a recent review of multiple human studies led by an epidemiologist at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.